Medafor Overview

  • Founded
  • 1999
  • Status
  • Private
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $200M
Latest Deal Amount

Medafor General Information


Developer and supplier of plant based hemostatic agents. The company develops an adjunctive hemostatic agent to control bleeding when conventional means are ineffective or impractical.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Surgical Devices
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 2700 Freeway Boulevard
  • Suite 800
  • Minneapolis, MN 55430
  • United States
+1 (877) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Medafor Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 19-Aug-2013 $200M 00.000 00000 Completed Generating Revenue
5. Later Stage VC 27-Sep-2012 00000 00.000 Completed Generating Revenue
4. Later Stage VC 07-Jan-2009 00.000 00.000 Completed Generating Revenue
3. Later Stage VC 07-Sep-2007 00000 00.000 Completed Generating Revenue
2. Later Stage VC 08-Mar-2005 $1.39M $2.22M Completed Generating Revenue
1. Early Stage VC 08-Mar-2004 $831K $831K Completed Generating Revenue
To view Medafor’s complete valuation and funding history, request access »

Medafor Executive Team (4)

Name Title Board Seat Contact Info
Kraig Black Chief Operating Officer & Executive Vice President, Corporate Development
Craig Wisman Chief Technology Officer
Gary Shope Chief Executive Officer & Board Member
You’re viewing 3 of 4 executive team members. Get the full list »

Medafor Board Members (5)

Name Representing Role Since
Gary Shope Self Chief Executive Officer & Board Member 000 0000
Gerald Van Eeckhout Self Board Member 000 0000
Michael Pasquale Self Board Member 000 0000
Paul Gray JD Self Board Member 000 0000
Robert Halverson Self Board Member 000 0000
To view Medafor’s complete board members history, request access »